KPV
Peptide ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
KPV is the C-terminal Lys-Pro-Val tripeptide of alpha-MSH studied for anti-inflammatory signaling in gut, skin, and immune models. It is not FDA-approved for human use and has no established clinical dose. Human evidence is very limited, so marketed gut-healing or anti-inflammatory protocols should be treated as experimental.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This safety record covers a controlled, investigational, or otherwise out-of-scope substance. It remains available for reference, but it is not part of NutriStack's public supplement publication set.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
KPV is a peptide most often used for anti-inflammatory activity in cell and animal models, studied in colitis models, interest in gut-barrier and skin inflammation. NutriStack rates the overall evidence as insufficient. A typical adult dose is No FDA-approved human dose; research protocols are model-specific, commonly taken as not recommended outside approved research. This profile indexes 3 sources.
The bottom line
Evidence rating insufficient. Most-documented uses: anti-inflammatory activity in cell and animal models, studied in colitis models, interest in gut-barrier and skin inflammation. 3 sources indexed (2000–2016), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
KPV appears to reproduce part of alpha-MSH anti-inflammatory activity, including reduced NF-kappaB signaling and pro-inflammatory cytokine expression in experimental systems. Oral delivery concepts often focus on PepT1 transport in intestinal epithelium, but human formulation, exposure, and outcome data remain inadequate. It should not be used to replace IBD, infection, or dermatologic care.1,2
Dosing & protocol.
Peptides are generally not reliably orally bioavailable unless a specific studied oral formulation is used. Human use of research-grade products is not appropriate.
What it actually costs.
Real-world pricing across three quality tiers. Assumes Oral Research Capsule.
Research-market pricing is not a dosing recommendation; human use is not FDA-approved unless specifically stated. Updated 2026-06-04.
Full safety detail.
Side effects
- Unknown long-term immune effects
- Nausea or GI discomfort
- Headache
- Injection-site reaction if misused
- Product contamination or mislabeling risk
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Reviews & position papers
1- 1alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugsCatania A et al. · Annals of the New York Academy of Sciences · 2006
KPV described as key alpha-MSH fragment
Mechanistic & preclinical
2- 2Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine modelViennois E et al. · Cancer Research · 2016
KPV reduced inflammatory signals in mice
- 3Alpha-melanocyte-stimulating hormone peptides inhibit HIV-1 expression in chronically infected promonocytic U1 cells and in acutely infected monocytesBohm M et al. · Journal of Immunology · 2000
KPV affected inflammatory transcription pathways
Common questions.
Quick answers about KPV, drawn from the data on this page.
What is KPV?
KPV is the C-terminal Lys-Pro-Val tripeptide of alpha-MSH studied for anti-inflammatory signaling in gut, skin, and immune models. It is not FDA-approved for human use and has no established clinical dose. Human evidence is very limited, so marketed gut-healing or anti-inflammatory protocols should be treated as experimental.
What is KPV used for?
Commonly cited benefits of KPV include: Anti-inflammatory activity in cell and animal models; Studied in colitis models; Interest in gut-barrier and skin inflammation; No FDA-approved indication. NutriStack rates the overall evidence as insufficient.
What is a typical dose of KPV?
A typical adult dose of KPV is No FDA-approved human dose; research protocols are model-specific. The commonly recommended form is Not recommended outside approved research. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of KPV?
Reported side effects include unknown long-term immune effects, nausea or gi discomfort, headache, injection-site reaction if misused, product contamination or mislabeling risk. This is educational information; check with a healthcare professional before use.
How strong is the evidence for KPV?
NutriStack rates this as Insufficient, meaning the body of evidence reviewed in NutriStack's tiering framework. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
KPV in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.